Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwideNEW YORK and IRVING, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Aesthetic Record as a key partner for the Aesthetics ...

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]

Core Insights - Obagi Medical has launched two new lip products, the Obagi Lip Therapy AHA + PHA Smoothing Micro-Peel and the Obagi Lip Therapy Soothe & Protect Lip Treatment SPF 30, as part of a targeted treatment protocol for lip care [1][2]. Product Details - The Lip Therapy protocol is designed for nightly rejuvenation and daily protection, focusing on the delicate lip area to improve texture, restore hydration, and protect against environmental stressors [2][5]. - The AHA + PHA Smoothing Micro-Peel features three resurfacing acids: Glycolic Acid, Lactic Acid, and Gluconolactone, along with Hyaluronic Acid and Argan Oil to enhance moisture retention and improve lip appearance [3][4]. - The Soothe & Protect Lip Treatment SPF 30 provides hydration and broad-spectrum sun protection, formulated with a plumping peptide complex, Calendula, Hyaluronic Acid, and Vitamin E to smooth fine lines and support the lip barrier [4]. Consumer Feedback - In consumer perception testing, a majority reported smoother, plumper, and more replenished lips immediately after application, with continued improvements in hydration and overall appearance within two weeks [5]. Company Background - Obagi Medical has over 35 years of experience in advanced skincare, initially recognized for its treatment of hyperpigmentation with the Obagi Nu-Derm® System, and is now the fastest-growing professional skincare brand in the U.S. as of 2024 [7]. Availability and Pricing - The Lip Therapy AHA + PHA Smoothing Micro-Peel is priced at $55, and the Soothe & Protect Lip Treatment SPF 30 is priced at $40, both available through professional channels and on Obagi.com starting February 3rd [6].

Core Insights - Obagi Medical has selected Platinum Dermatology Partners as the launch partner for its ALOHA Program, focusing on the integration of clinical evidence into everyday practice [1][2] Company Overview - Obagi Medical is recognized for its innovative physician-dispensed skincare solutions and has over 35 years of experience in the industry, particularly in treating skin concerns like hyperpigmentation and premature aging [6] - Platinum Dermatology Partners operates over 120 locations with nearly 400 providers across multiple states, emphasizing a collaborative practice model to enhance patient care [7] Program Details - The ALOHA Program aims to generate real-world data to validate the safety and efficacy of Obagi's products, specifically the saypha MagIQ injectable, through hands-on experience and structured evaluations [2][3] - Initial findings from the ALOHA Program will be presented at the annual Platinum Summit in September, showcasing the benefits of the new product within the Platinum network [4] Strategic Intent - The partnership with Platinum signifies Obagi's commitment to launching new injectables based on robust clinical evidence and integrated patient outcomes, aligning with the company's innovative approach to product development [5]

Core Insights - Obagi Medical has launched the ALOHA Program aimed at driving innovation in aesthetic practices through real-world evidence and insights [1][2] - The program will support the introduction of Obagi saypha MagIQ™, the first FDA-approved injectable hyaluronic acid filler from the company, featuring high usable HA content and a predictable injection profile [1][2] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare with over 35 years of experience, initially known for its Obagi Nu-Derm System targeting hyperpigmentation [3] - The company is the fastest-growing professional skincare brand in the U.S. as of 2024, focusing on various skin concerns including aging, photodamage, and acne [3] Program Details - The ALOHA Program will gather real-world data from diverse practice settings to demonstrate the effectiveness of Obagi saypha MagIQ™ and its skincare products in enhancing practice success and patient satisfaction [2] - Participants in the program will provide structured feedback through standardized surveys, creating a comprehensive evaluation of the new HA injectable beyond traditional clinical trials [2] Industry Context - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, ensuring agility and market responsiveness [4] - The company's strategy includes leveraging operational scale and expertise in managing beauty brands to mitigate category fluctuations and enhance brand performance [4]

Core Insights - Waldencast plc reported a 5.6% year-over-year increase in net revenue for Q2 2025, reaching $66.8 million, with an Adjusted EBITDA Margin of 5.0% [2][10] - The company experienced contrasting performances across its brands, with Obagi Medical showing strong growth while Milk Makeup faced challenges in international markets [2][6] - Waldencast has updated its FY 2025 guidance to reflect current trends and investments aimed at long-term growth [1][8] Obagi Medical - Obagi Medical achieved double-digit net revenue growth in Q3 2025, driven by strong e-commerce and international market performance [3][19] - The brand is preparing for the launch of Obagi Saypha®, which will double its addressable market in the U.S. [3][4] - The sale of the Obagi Japan trademark for $82.5 million and credit facility refinancing has strengthened the company's balance sheet [5][8] Milk Makeup - Milk Makeup's net revenue for Q3 2025 was $25.2 million, a decline of 20.1% compared to Q3 2024, despite an 8% increase in U.S. consumption [20][23] - The brand's growth in the U.S. was supported by retail expansion and successful product launches, but international performance was weaker [6][20] - Transformation initiatives are being implemented to revitalize the brand, including team restructuring and increased investment in international markets [7][8] Financial Performance - For H1 2025, Waldencast's net revenue increased by 0.5% year-over-year to $132.3 million, with a net loss of $185.2 million primarily due to impairment charges [13][14] - Adjusted EBITDA for H1 2025 was $7.7 million, representing a margin of 5.8%, down from 13.4% in H1 2024 [15][16] - Q3 2025 net revenue decreased by 3.4% year-over-year to $67.8 million, with Obagi Medical contributing $42.6 million and Milk Makeup $25.2 million [18][23] Strategic Initiatives - Waldencast is conducting a strategic review to maximize shareholder value, having retained Lazard as a financial advisor [8][9] - The company is focused on building a leading dermatological megabrand at the intersection of skincare and medical aesthetics [4][5] - Continued investments in innovation, digital capabilities, and new distribution channels are expected to drive sustainable growth [25][24]

Core Insights - Obagi Medical's data on the saypha ChIQ™ product was recognized as one of the top 10 cosmetic oral abstract presentations at the ASDS Annual Meeting, indicating strong industry validation and interest in the product [1][2] - The pivotal study comparing Obagi saypha ChIQ™ with Juvéderm Voluma® XC demonstrated non-inferiority in effectiveness and safety, achieving high patient satisfaction across diverse skin types [2][6] - The Obagi Nu-Cil® BioStim™ Scalp Serum showed promising interim results in improving scalp health and hair appearance after three months of use [3][5] Product Development and Innovation - Obagi saypha ChIQ™ utilizes proprietary MACRO Core Technology, which creates a stable 3D HA matrix for natural-looking results, and is currently under FDA review [6] - The BioStim™ Complex in the Nu-Cil® BioStim™ Scalp Serum includes clinically proven actives such as biotin, amino acids, and peptides, aimed at promoting scalp health and strengthening hair follicles [5][6] - Obagi Medical's commitment to innovation is reflected in its extensive research and development efforts, as well as the introduction of new products with established safety profiles and high patient satisfaction [5][7] Market Position and Growth - Obagi Medical is recognized as the fastest-growing professional skincare brand in the U.S. in 2024, highlighting its strong market presence and consumer demand [7][8] - The company's strategic focus on expanding its aesthetic injectable market is supported by the positive reception of its products at industry events [5][6] - Waldencast, the parent company of Obagi Medical, aims to build a global beauty and wellness platform, enhancing operational scale and market responsiveness for its brands [8]

Core Insights - Obagi Medical has launched the Nu-Cil BioStim™ Scalp Serum, a clinically proven product designed to promote fuller and denser-looking hair by improving scalp health [1][5]. Product Details - The Nu-Cil BioStim™ Scalp Serum is formulated with the BioStim™ Complex, which includes Biotin, Amino Acids, Peptides, and 18 essential Nutrients, B Vitamins, and Phytoactives to enhance scalp health and strengthen hair follicles [2]. - The serum is clinically proven to reduce dry fallen hair by 74% in three months and improve hair volume by 52% in less than six months [9]. Market Context - Hair loss and thinning are significant concerns, with two in three Americans over age 35 experiencing these issues [4]. - There is a growing demand for skincare-grade ingredients in hair care, with 56% of U.S. women seeking such products [4]. Company Background - Obagi Medical has over 35 years of experience in advanced skincare and is recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [6]. - The company aims to meet evolving consumer needs with science-driven, high-performance formulas [5].

Core Insights - Waldencast plc has received FDA approval for Obagi saypha MagIQ™ injectable hyaluronic acid gel, marking its entry into the U.S. HA dermal filler market and aiming to double Obagi Medical's addressable market to approximately $4.2 billion by 2029 [1][2] Company Overview - Waldencast aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands, with a focus on operational scale and market responsiveness [8] - Obagi Medical is recognized for its advanced skincare line with over 35 years of experience, initially known for treating hyperpigmentation [9] - Croma-Pharma GmbH, a partner in developing Obagi saypha MagIQ™, has over 40 years of expertise in HA-based treatments and has produced more than 110 million syringes [4][10] Product Details - Obagi saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix, providing natural-looking results with high HA content and consistent gel distribution [3] - The product is expected to set a new standard in HA dermal fillers in the U.S., with a strong safety profile and proven innovation [2][5] Market Strategy - The launch of Obagi saypha MagIQ™ is planned for 2026, leveraging Obagi Medical's established network of practices and aesthetic professionals to enhance value for providers and patients [2][5] - The U.S. Nasolabial Fold pivotal study for Obagi saypha MagIQ™ included 270 patients and demonstrated non-inferiority to the control with similar safety profiles [5][6]

Core Business Update - Waldencast plc reported strong performance in H1 2025, with significant revenue growth in its core strategic channels, particularly in the U.S. and international markets [1][4][14] - The acquisition of Novaestiq Corp. is a strategic move that doubles Obagi Medical's addressable market in the U.S., marking its entry into the aesthetics space [6][17] - Milk Makeup experienced a strong retail sales performance in the U.S., with sales accelerating to the high-20s percentage growth in Q2 2025 [3][19] Financial Performance - The company anticipates net revenue growth in the low to mid-single digits for FY 2025, reflecting a more moderated industry environment [7][22] - Adjusted EBITDA margins are expected to be in the low to mid-teens, indicating strong operating discipline and cost management [7][22] Strategic Initiatives - Waldencast is conducting a strategic review to explore various alternatives aimed at maximizing shareholder value, with Lazard retained as a financial advisor [8][9] - The company is focused on refining its distribution strategy by exiting non-equity building distribution points and investing in supply chain improvements [5][6] Brand Performance - Obagi Medical achieved high single-digit growth in U.S. core strategic channels, with international growth accelerating to mid-40s in Q2 2025 [14][16] - Milk Makeup's digital presence expanded with the launch of Amazon Premium Beauty, contributing to its revenue growth [20][25] Market Challenges - The company faces challenges in international markets, including soft consumption and destocking by key retailers, which necessitates incremental investment [3][5][25] - Ongoing out-of-stock issues have limited overall growth, although improvements in stock levels are expected in the third quarter [5][6]